Sensitivity analyses for the primary outcomes
| Intervention . | Outcome . | Main analysis . | ROB: excluding studies at high ROB . |
|---|---|---|---|
| Prophylactic immunoglobulin | All-cause mortality | RR 1.35 (95% CI, 0.57-3.18); including 164 participants from 2 studies | RR 1.35 (95% CI, 0.57-3.18); including 164 participants from 2 studies |
| Prophylactic immunoglobulin | Patients with ≥1 CDI | RR 0.72 (95% CI, 0.54-0.96); including 267 participants from 5 studies | RR 0.80 (95% CI, 0.62-1.04); including 207 participants from 4 studies |
| Prophylactic antibiotic | All-cause mortality | RR 1.11 (95% CI, 0.85-1.45); including 1533 participants from 4 studies | RR 1.03 (95% CI, 0.68-1.56); including 1035 participants from 2 studies |
| Prophylactic antibiotic | Patients with ≥1 CDI | RR 0.93 (95% CI, 0.79-1.08); including 1576 participants from 5 studies | RR 0.87 (95% CI, 0.76-1.00); including 1035 participants from 2 studies |
| VZV vaccination | All-cause mortality | RR 0.92 (95% CI, 0.75-1.14); including 3738 participants from 4 studies | RR 0.92 (95% CI, 0.75-1.14); including 3738 participants from 4 studies |
| VZV vaccination | Patients with ≥1 CDI | RR 0.36 (95% CI, 0.29-0.44); including 3515 participants from 5 studies | RR 0.36 (95% CI, 0.29-0.44); including 3515 participants from 5 studies |
| Intervention . | Outcome . | Main analysis . | ROB: excluding studies at high ROB . |
|---|---|---|---|
| Prophylactic immunoglobulin | All-cause mortality | RR 1.35 (95% CI, 0.57-3.18); including 164 participants from 2 studies | RR 1.35 (95% CI, 0.57-3.18); including 164 participants from 2 studies |
| Prophylactic immunoglobulin | Patients with ≥1 CDI | RR 0.72 (95% CI, 0.54-0.96); including 267 participants from 5 studies | RR 0.80 (95% CI, 0.62-1.04); including 207 participants from 4 studies |
| Prophylactic antibiotic | All-cause mortality | RR 1.11 (95% CI, 0.85-1.45); including 1533 participants from 4 studies | RR 1.03 (95% CI, 0.68-1.56); including 1035 participants from 2 studies |
| Prophylactic antibiotic | Patients with ≥1 CDI | RR 0.93 (95% CI, 0.79-1.08); including 1576 participants from 5 studies | RR 0.87 (95% CI, 0.76-1.00); including 1035 participants from 2 studies |
| VZV vaccination | All-cause mortality | RR 0.92 (95% CI, 0.75-1.14); including 3738 participants from 4 studies | RR 0.92 (95% CI, 0.75-1.14); including 3738 participants from 4 studies |
| VZV vaccination | Patients with ≥1 CDI | RR 0.36 (95% CI, 0.29-0.44); including 3515 participants from 5 studies | RR 0.36 (95% CI, 0.29-0.44); including 3515 participants from 5 studies |